OTCMKTS:TLPPF Telix Pharmaceuticals (TLPPF) Stock Price, News & Analysis $11.67 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFinancialsNews and TrendsSEC Filings About Telix Pharmaceuticals Stock (OTCMKTS:TLPPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Telix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.67▼$11.6750-Day Range$9.49▼$12.5552-Week Range$5.91▼$13.00VolumeN/AAverage Volume4,157 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company Overview Telix Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer imaging and treatment. Its platform combines radioactive isotopes with targeting molecules designed to identify or bind to specific biological markers associated with disease. The company’s principal commercial product is Illuccix, a gallium-68 PSMA-PET imaging agent used to help detect and manage prostate cancer. Telix is also developing a pipeline of diagnostic and therapeutic radiopharmaceuticals targeting cancers including kidney, brain, and prostate tumors, as well as other medical conditions. Founded in 2015 and headquartered in Melbourne, Australia, Telix serves healthcare markets across Australia, the United States, Europe, and other international regions through regulatory approvals, commercial partnerships, and distribution arrangements. Christian Behrenbruch is the company’s managing director and group chief executive officer.AI Generated. May Contain Errors. Read More Receive TLPPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLPPF Stock News HeadlinesAustralia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billionSeptember 20, 2026 | reuters.comAnalysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and Takeda Pharmaceutical Co (OtherTKPHF)August 24, 2026 | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 27 at 1:00 AM | Weiss Ratings (Ad)Analysts Are Bullish on These Healthcare Stocks: Telix Pharmaceuticals (TLPPF), Impedimed Limited (IPDQF)July 29, 2026 | theglobeandmail.comJ.P. Morgan Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)July 25, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Pyxis Oncology (PYXS) and Telix Pharmaceuticals (OtherTLPPF)July 21, 2026 | theglobeandmail.comBell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)July 21, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Telix Pharmaceuticals (OtherTLPPF)May 27, 2026 | theglobeandmail.comSee More Headlines TLPPF Stock Analysis - Frequently Asked Questions How have TLPPF shares performed this year? Telix Pharmaceuticals' stock was trading at $7.7361 at the start of the year. Since then, TLPPF stock has increased by 50.9% and is now trading at $11.67. How do I buy shares of Telix Pharmaceuticals? Shares of TLPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:TLPPF CIK2007191 Webtelixpharma.com Phone61-3-3093-3897FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Price Target for Telix Pharmaceuticals$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+71.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:TLPPF) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLPPF Stock Alerts